Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on Opicapone Bioavailability
NCT03116308Phase 1Completed
- Sponsor
- BIAL
- Start
- Nov 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by BIAL. Primary endpoints: Maximum observed effect on COMT activity at Day 10, Time to occurrence of Emax at Day 10 and 1 more. Started Nov 2014; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03116308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116308.